OCUL (Ocular Therapeutix) Cyclically Adjusted FCF per Share: $-1.45 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCUL Ocular Therapeutix Inc OCUL
55 GF Score
Price $11.10
GF Value $4.56
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocular Therapeutix Cyclically Adjusted FCF per Share?

Ocular Therapeutix OCUL -5.54% 55 Cyclically Adjusted FCF per Share is $-1.45 as of Jun. 2026. GuruFocus rates OCUL with a GF Score™ of 55/100 and a GF Value™ of $4.56 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ocular Therapeutix's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-0.314. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.45 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ocular Therapeutix was 12.60% per year. The lowest was 12.60% per year. And the median was 12.60% per year.

As of today (2026-08-20), Ocular Therapeutix's current stock price is $11.10. Ocular Therapeutix's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-1.45. Ocular Therapeutix's Cyclically Adjusted Price-to-FCF of today is .


Ocular Therapeutix  (NAS:OCUL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ocular Therapeutix Cyclically Adjusted FCF per Share Related Terms


Ocular Therapeutix Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Cyclically Adjusted FCF per Share Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -2.19 -1.87 -1.51 -1.46

Ocular Therapeutix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.50 -1.48 -1.46 -1.46 -1.45

OCUL vs KARD, GHRS, FTRE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted Price-to-FCF falls into.


OCUL
55GF Score
Ocular Therapeutix Inc OCUL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocular Therapeutix's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.314/333.9520*333.9520
=-0.314

Current CPI (Jun. 2026) = 333.9520.

Ocular Therapeutix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.330 241.428 -0.456
201612 -0.333 241.432 -0.461
201703 -0.587 243.801 -0.804
201706 -0.521 244.955 -0.710
201709 -0.564 246.819 -0.763
201712 -0.371 246.524 -0.503
201803 -0.369 249.554 -0.494
201806 -0.341 251.989 -0.452
201809 -0.291 252.439 -0.385
201812 -0.343 251.233 -0.456
201903 -0.455 254.202 -0.598
201906 -0.458 256.143 -0.597
201909 -0.379 256.759 -0.493
201912 -0.410 256.974 -0.533
202003 -0.368 258.115 -0.476
202006 -0.260 257.797 -0.337
202009 -0.202 260.280 -0.259
202012 -0.092 260.474 -0.118
202103 -0.201 264.877 -0.253
202106 -0.246 271.696 -0.302
202109 -0.155 274.310 -0.189
202112 -0.192 278.802 -0.230
202203 -0.229 287.504 -0.266
202206 -0.138 296.311 -0.156
202209 -0.181 296.808 -0.204
202212 -0.231 296.797 -0.260
202303 -0.302 301.836 -0.334
202306 -0.283 305.109 -0.310
202309 -0.094 307.789 -0.102
202312 -0.254 306.746 -0.277
202403 -0.259 312.332 -0.277
202406 -0.154 314.175 -0.164
202409 -0.219 315.301 -0.232
202412 -0.236 315.605 -0.250
202503 -0.275 319.799 -0.287
202506 -0.327 322.561 -0.339
202509 -0.308 324.800 -0.317
202512 -0.256 324.054 -0.264
202603 -0.315 330.213 -0.319
202606 -0.314 333.952 -0.314

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.45 mean?
Ocular Therapeutix (OCUL) has a Cyclically Adjusted FCF per Share of $-1.45 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors.
Is Ocular Therapeutix's Cyclically Adjusted FCF per Share too high?
Ocular Therapeutix's current Cyclically Adjusted FCF per Share is $-1.45. Overall, Ocular Therapeutix has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Cyclically Adjusted FCF per Share compare to KARD and GHRS?
Ocular Therapeutix's Cyclically Adjusted FCF per Share of $-1.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current Cyclically Adjusted FCF per Share is $-1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.56, compared to a current price of $11.10 — trading 143.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-1.45. Ocular Therapeutix's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current Cyclically Adjusted FCF per Share is $-1.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (OCUL) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of $11.10 is trading 143.4% above its estimated GF Value™ of $4.56. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for OCUL:

  • Cyclically Adjusted FCF per Share: $-1.45
  • GF Value™: $4.56 vs. price of $11.10 (143.4% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges 0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
55GF Score

Get the complete analysis for OCUL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.10
Price
$4.56
GF Value